AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 14.370-14.570 for the period, compared to the consensus estimate of 14.260. The company issued revenue guidance of -, compared to the consensus revenue estimate of $67.1 billion.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABBV. Guggenheim lifted their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.17.

AbbVie Stock Down 4.8%

ABBV stock traded down $10.92 during trading on Wednesday, reaching $214.75. The stock had a trading volume of 6,789,990 shares, compared to its average volume of 7,222,098. AbbVie has a one year low of $164.39 and a one year high of $244.81. The company’s 50 day moving average is $224.20 and its two-hundred day moving average is $219.16. The company has a market capitalization of $379.54 billion, a price-to-earnings ratio of 162.69, a P/E/G ratio of 0.93 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, missing analysts’ consensus estimates of $3.37 by ($0.66). AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS. As a group, research analysts predict that AbbVie will post 12.31 earnings per share for the current fiscal year.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 adjusted results beat revenue/adjusted‑EPS expectations: AbbVie reported adjusted EPS of $2.71 and net revenue of $16.62B, which topped many street estimates and shows continuing top‑line momentum. Read More.
• Positive Sentiment: Raised 2026 adjusted EPS guidance: AbbVie set FY2026 adjusted EPS guidance at $14.37–$14.57, above consensus, signaling management expects continued profit power from newer immunology drugs. Read More.
• Neutral Sentiment: Immunology strength driving growth but offsets in other areas: Skyrizi and Rinvoq continue to grow strongly and are supporting overall revenue expansion, while other segments show mixed results. This shapes a generally positive medium‑term story but with uneven segment trends. Read More.
• Neutral Sentiment: Pipeline/regulatory progress is incremental upside: AbbVie submitted filings for Rinvoq in vitiligo, a potential label expansion that could add future revenue if approved — positive but not immediate. Read More.
• Negative Sentiment: Market reaction: shares fell despite the beat-and-raise — several outlets note investors sold into strength. Short‑term investor focus appears to be on nuances between GAAP vs. adjusted metrics and near‑term segment weakness rather than the longer‑term guidance lift. Read More.
• Negative Sentiment: Headwinds and accounting items: Humira sales continue to decline yr/yr (but less than feared), oncology and aesthetics showed softness, and Q4 included IPR&D/milestone charges that reduced GAAP EPS — all factors that can spook short‑term traders. Read More.
• Negative Sentiment: Valuation sensitivity: with the stock trading at a rich multiple in some metrics, even modest execution concerns or mixed headlines can trigger outsized intraday moves. (See analyst commentary and market notes.) Read More.

Institutional Investors Weigh In On AbbVie

Several large investors have recently modified their holdings of the stock. Revolve Wealth Partners LLC raised its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Brighton Jones LLC increased its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Schnieders Capital Management LLC. raised its stake in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the period. SIH Partners LLLP purchased a new stake in AbbVie during the third quarter valued at about $424,000. Finally, Vista Capital Partners Inc. boosted its position in AbbVie by 10.6% during the second quarter. Vista Capital Partners Inc. now owns 2,235 shares of the company’s stock worth $415,000 after purchasing an additional 214 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.